Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 19:14:1272754.
doi: 10.3389/fmicb.2023.1272754. eCollection 2023.

Comparing technology and regulatory landscape of probiotics as food, dietary supplements and live biotherapeutics

Irina Spacova  1 , Sylvie Binda  2 , Jessica Anne Ter Haar  3 , Solange Henoud  2 , Sophie Legrain-Raspaud  4 , James Dekker  5 , Jordi Espadaler-Mazo  6 , Philippe Langella  7 , Rebeca Martín  7 , Marco Pane  8 , Arthur C Ouwehand  9
Affiliations
Review

Comparing technology and regulatory landscape of probiotics as food, dietary supplements and live biotherapeutics

Irina Spacova et al. Front Microbiol. .

Abstract

Application of beneficial microorganisms as probiotics targets a broad range of intended uses, from maintaining health and supporting normal bodily functions to curing and preventing diseases. Currently, three main regulatory fields of probiotic products can be defined depending on their intended use: the more similar probiotic foods and probiotic dietary supplements, and live biotherapeutic products. However, it is not always straightforward to classify a probiotic product into one of these categories. The regulatory nuances of developing, manufacturing, investigating and applying each category of probiotic products are not universal, and not always apparent to those unfamiliar with the various global probiotic regulatory guidelines. Various global markets can be significantly different regarding legislation, possible claims, market value and quality requirements for the development and commercialization of probiotic products. Furthermore, different probiotic product categories are also linked with variable costs at different stages of product development. This review outlines the current landscape comparing probiotic foods, probiotic dietary supplements, and live biotherapeutics as probiotic products from a regulatory lens, focusing on product development, manufacturing and production, and clinical research agenda. The aim is to inform and promote a better understanding among stakeholders by outlining the expectations and performance for each probiotic product category, depending on their intended use and targeted geographical region.

Keywords: clinical trials; drug; manufacturing; pharmabiotics; probiotic; product development; regulation; supplement.

PubMed Disclaimer

Conflict of interest statement

SB and SH were employed by Lallemand Health Solutions. JH was employed by the International Probiotics Association. SL-R was employed by Lesaffre. JD was employed by Fonterra. JE-M was employed by AB-Biotics SA (Kaneka Group). MP was employed by Probiotical Research. AO was employed by IFF Health. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Overview of main regulatory categories of probiotics (PF, PDS, LBPs). Of note, the use of PF and PDS is not excluded in a diseased individual to support health for similar purposes as in healthy individuals, however here we emphasize the target population from a regulatory perspective. Elaborated by the authors from various sources.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Aguilar-Toala J. E., Arioli S., Behare P., Belzer C., Berni Canani R., Chatel J. M., et al. (2021). Postbiotics - when simplification fails to clarify. Nat. Rev. Gastroenterol. Hepatol. 18 825–826. - PubMed
    1. Binda S., Hill C., Johansen E., Obis D., Pot B., Sanders M. E., et al. (2020). Criteria to qualify microorganisms as “probiotic” in foods and dietary supplements. Front. Microbiol. 11:1662. 10.3389/fmicb.2020.01662 - DOI - PMC - PubMed
    1. CFI Team (2023). Current Good Manufacturing Practices (CGMPs). Available online at: https://corporatefinanceinstitute.com/resources/valuation/current-good-m... (accessed October 15, 2023).
    1. Chieffi D., Fanelli F., Fusco V. (2022). Legislation of probiotic foods and supplements. Probiotics for human nutrition in health and disease. Amsterdam: Elsevier.
    1. Cordaillat-Simmons M., Rouanet A., Pot B. (2020). Live biotherapeutic products: the importance of a defined regulatory framework. Exp. Mol. Med. 52 1397–1406. 10.1038/s12276-020-0437-6 - DOI - PMC - PubMed

LinkOut - more resources